Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safety First: FDA Unveils New Postmarketing Management Process For Safety

Executive Summary

With FDA's latest new initiatives to address problems with postmarketing safety processes -Safety First/Safe Use - the agency is aiming at applying PDUFA-style management to postmarketing drug safety issues

You may also be interested in...



CDER To Pilot Test New Framework For Classifying Drug Safety Issues

A recent draft guidance spells out the agency’s proposed approach to classifying significant post-marketing safety concerns for “standard,” “priority” or “emergency” handling. After pilot testing the framework over the next year, CDER intends to develop milestones for regulatory action on safety issues, similar to NDA/BLA action dates under PDUFA.

CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues

Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.

CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues

Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel